1. Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis
- Author
-
Kirsten Reuter-Jessen, Tessa Rosenthal, Laura Lukat, Annalen Bleckmann, Sara Hugo, Katja Schmitz, Achim Rittmeyer, Juliane Schnalke, Hans-Ulrich Schildhaus, Marc Hinterthaner, Wolfgang Körber, Dana Alina Cron, Joachim Moecks, Tabea Hugo, and Tobias Overbeck
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,business.industry ,Medizin ,non-small cell lung cancer (NSCLC) ,medicine.disease ,MET Exon 14 Skipping Mutation ,3. Good health ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,ROS1 ,Copy-number variation ,Stage (cooking) ,Lung cancer ,business ,Gene ,Pathological - Abstract
Ca Schildhaus Background: MET amplifications occur in human tumors, including non-small cell lung cancer (NSCLC). MET inhibitors have demonstrated some clinical activity in MET amplified NSCLC, presumably with a gene dose effect. However, the definition of MET positivity or MET amplification as a potential oncogenic driver is still under debate. In this study, we aimed to establish the molecular subgroup of NSCLC with the highest unequivocal MET amplification level and to describe the prevalence, and histologic and clinical phenotype of this subgroup. Methods: A total of 373 unselected patients with NSCLC were consecutively tested for MET gene copy number (GCN) by FISH. Mean GCN, MET/CEN7 ratio and other FISH parameters were identified and correlated with morphological and molecular pathological characteristics of the tumors as well as with clinical data. Results: Based on the variability of obtained data a top-level category of MET amplification was newly defined (>90th percentile of average GCN; >= 10 MET gene copies per tumor cell). This criterion was fulfilled in 2% of analyzed tumors. These tumors were exclusively poorly differentiated adenocarcinomas with a predominant solid subtype and pleomorphic features. Rarely, co-alterations were detected (KRAS mutation or MET exon 14 skipping mutation). In this top-level group, there were no EGFR mutations or ALK or ROS1 alterations. The most important clinical feature was a significantly shortened overall survival (HR 3.61; median OS 8.2 vs. 23.6 months). Worse prognosis did not depend on initial stage or treatment. Conclusions: The newly defined top-level category of MET amplification in NSCLC defines a specific subgroup of pulmonary adenocarcinoma with adverse prognosis and characteristic morphological features. Lower levels of MET gene copy number seem to have probably no specific value as a prognostic or predictive biomarker.
- Published
- 2020
- Full Text
- View/download PDF